{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T05:43:20Z","timestamp":1781070200635,"version":"3.54.1"},"reference-count":46,"publisher":"Impact Journals, LLC","issue":"47","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,11,22]]},"DOI":"10.18632\/oncotarget.12943","type":"journal-article","created":{"date-parts":[[2016,10,27]],"date-time":"2016-10-27T18:11:45Z","timestamp":1477591905000},"page":"78083-78094","source":"Crossref","is-referenced-by-count":10,"title":["Transposon-mediated generation of <i>BCR-ABL1<\/i>-expressing transgenic cell lines for unbiased sensitivity testing of tyrosine kinase inhibitors"],"prefix":"10.18632","volume":"7","author":[{"given":"Konstantin","family":"Byrgazov","sequence":"first","affiliation":[{"name":"Children's Cancer Research Institute, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal Blanche","family":"Lucini","sequence":"additional","affiliation":[{"name":"Children's Cancer Research Institute, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Berkowitsch","sequence":"additional","affiliation":[{"name":"Children's Cancer Research Institute, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margit","family":"Koenig","sequence":"additional","affiliation":[{"name":"Children's Cancer Research Institute, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar A.","family":"Haas","sequence":"additional","affiliation":[{"name":"Children's Cancer Research Institute, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Hoermann","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Valent","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lion","sequence":"additional","affiliation":[{"name":"Children's Cancer Research Institute, Vienna, Austria"},{"name":"Department of Pediatrics, Medical University of Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,10,27]]},"reference":[{"key":"1","first-page":"1013","article-title":"Chromosome studies in human leukemia. II. Chronic granulocytic leukemia","volume":"27","author":"Hungerford","year":"1961","journal-title":"J Natl Cancer Inst"},{"key":"2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","article-title":"Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22","volume":"36","author":"Grosveld","year":"1984","journal-title":"Cell"},{"key":"3","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1177\/1947601912458584","article-title":"Structure, regulation, signaling, and targeting of abl kinases in cancer","volume":"3","author":"Hantschel","year":"2012","journal-title":"Genes Cancer"},{"key":"4","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Powell","year":"2006","journal-title":"N Engl J Med"},{"key":"5","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"key":"6","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Rusch","year":"2014","journal-title":"N Engl J Med"},{"key":"7","doi-asserted-by":"publisher","first-page":"e261","DOI":"10.3324\/haematol.2014.117424","article-title":"Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates","volume":"100","author":"Rijneveld","year":"2015","journal-title":"Haematologica"},{"key":"8","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"Marin","year":"2008","journal-title":"J Clin Oncol"},{"key":"9","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1038\/leu.2008.225","article-title":"A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials","volume":"22","author":"Clark","year":"2008","journal-title":"Leukemia"},{"key":"10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/MOH.0b013e32834399ef","article-title":"Mutational analysis in chronic myeloid leukemia: when and what to do?","volume":"18","author":"Hughes","year":"2011","journal-title":"Curr Opin Hematol"},{"key":"11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/leu.2010.238","article-title":"Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia","volume":"25","author":"Talpaz","year":"2011","journal-title":"Leukemia"},{"key":"12","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"13","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","article-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity","volume":"110","author":"Hughes","year":"2007","journal-title":"Blood"},{"key":"14","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1182\/blood.V90.12.4947","article-title":"CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins","volume":"90","author":"Druker","year":"1997","journal-title":"Blood"},{"key":"15","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Daley","year":"2005","journal-title":"Cancer Cell"},{"key":"16","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-06-0980","article-title":"Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells","volume":"12","author":"Bhalla","year":"2006","journal-title":"Clin Cancer Res"},{"key":"17","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants","volume":"27","author":"Boschelli","year":"2009","journal-title":"J Clin Oncol"},{"key":"18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"Loriaux","year":"2009","journal-title":"Cancer Cell"},{"key":"19","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"Kornblau","year":"2014","journal-title":"Cancer Cell"},{"key":"20","doi-asserted-by":"crossref","first-page":"9312","DOI":"10.1073\/pnas.85.23.9312","article-title":"Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr\/abl protein","volume":"85","author":"Baltimore","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"key":"21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/CCO.0b013e328011a25f","article-title":"Ba\/F3 cells and their use in kinase drug discovery","volume":"19","author":"Adrian","year":"2007","journal-title":"Curr Opin Oncol"},{"key":"22","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1089\/104303401753153947","article-title":"Systematic determination of the packaging limit of lentiviral vectors","volume":"12","author":"Sutton","year":"2001","journal-title":"Hum Gene Ther"},{"key":"23","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1002\/jgm.1052","article-title":"Optimized production and concentration of lentiviral vectors containing large inserts","volume":"9","author":"Foerster","year":"2007","journal-title":"J Gene Med"},{"key":"24","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1182\/blood-2002-07-2238","article-title":"Lentiviral vector transduction of NOD\/SCID repopulating cells results in multiple vector integrations per transduced cell: risk of insertional mutagenesis","volume":"101","author":"Karlsson","year":"2003","journal-title":"Blood"},{"key":"25","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/gt.2010.163","article-title":"Quantification of lentiviral vector copy numbers in individual hematopoietic colony-forming cells shows vector dose-dependent effects on the frequency and level of transduction","volume":"18","author":"Galy","year":"2011","journal-title":"Gene Ther"},{"key":"26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/gtc.12183","article-title":"Experimental design for stable genetic manipulation in mammalian cell lines: lentivirus and alternatives","volume":"20","author":"Saunders","year":"2015","journal-title":"Genes Cells"},{"key":"27","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0092-8674(02)00864-4","article-title":"HIV-1 integration in the human genome favors active genes and local hotspots","volume":"110","author":"Bushman","year":"2002","journal-title":"Cell"},{"key":"28","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1182\/blood.V122.21.3992.3992","article-title":"Comprehensive Analysis Of The In Vitro Potency Of Ponatinib, and All Other Approved BCR-ABL Tyrosine Kinase Inhibitors (TKIs), Against a Panel Of Single and Compound BCR-ABL Mutants","volume":"122","author":"Rivera","year":"2013","journal-title":"Blood"},{"key":"29","first-page":"1416","article-title":"Resistance Profiling of BCR-ABL Compound Mutations Linked to Tyrosine Kinase Inhibitor Therapy Failure in Chronic Myeloid Leukemia","volume":"118","author":"O'Hare","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"key":"30","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0022-2836(02)00991-9","article-title":"Common physical properties of DNA affecting target site selection of sleeping beauty and other Tc1\/mariner transposable elements","volume":"323","author":"Ivics","year":"2002","journal-title":"J Mol Biol"},{"key":"31","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1182\/blood-2009-03-210005","article-title":"Stable gene transfer and expression in cord blood-derived CD34+ hematopoietic stem and progenitor cells by a hyperactive Sleeping Beauty transposon system","volume":"114","author":"Zhou","year":"2009","journal-title":"Blood"},{"key":"32","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.canlet.2014.06.016","article-title":"Functional characterisation of different MLL fusion proteins by using inducible Sleeping Beauty vectors","volume":"352","author":"Marschalek","year":"2014","journal-title":"Cancer Lett"},{"key":"33","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.canlet.2012.12.023","article-title":"Functional analysis of the two reciprocal fusion genes MLL-NEBL and NEBL-MLL reveal their oncogenic potential","volume":"332","author":"Marschalek","year":"2013","journal-title":"Cancer Lett"},{"key":"34","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1182\/blood-2014-04-570960","article-title":"The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia","volume":"125","author":"Strehl","year":"2015","journal-title":"Blood"},{"key":"35","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1093\/nar\/gks213","article-title":"Combination of Sleeping Beauty transposition and chemically induced dimerization selection for robust production of engineered cells","volume":"40","author":"Pun","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"36","doi-asserted-by":"publisher","first-page":"E125","DOI":"10.1002\/ajh.23338","article-title":"Three novel patient-derived BCR\/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors","volume":"87","author":"Gambacorti-Passerini","year":"2012","journal-title":"Am J Hematol"},{"key":"37","doi-asserted-by":"crossref","first-page":"23255","DOI":"10.1074\/jbc.271.38.23255","article-title":"The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene","volume":"271","author":"Sawyers","year":"1996","journal-title":"J Biol Chem"},{"key":"38","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/sj.leu.2401010","article-title":"Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR\/ABL-transformed cells","volume":"12","author":"Salgia","year":"1998","journal-title":"Leukemia"},{"key":"39","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency","volume":"117","author":"Sawyers","year":"2007","journal-title":"J Clin Invest"},{"key":"40","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/biot.201400821","article-title":"Optimized Sleeping Beauty transposons rapidly generate stable transgenic cell lines","volume":"10","author":"Marschalek","year":"2015","journal-title":"Biotechnol J"},{"key":"41","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.3892\/ol.2013.1225","article-title":"Multiple copies of BCR-ABL fusion gene on two isodicentric Philadelphia chromosomes in an imatinib mesylate-resistant chronic myeloid leukemia patient","volume":"5","author":"Liehr","year":"2013","journal-title":"Oncol Lett"},{"key":"42","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Sawyers","year":"2001","journal-title":"Science"},{"key":"43","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(03)00979-3","article-title":"Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias","volume":"4","author":"Scapozza","year":"2003","journal-title":"Lancet Oncol"},{"key":"44","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/leu.2014.256","article-title":"Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment","volume":"29","author":"White","year":"2015","journal-title":"Leukemia"},{"key":"45","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1182\/blood-2006-11-055723","article-title":"Targeting of heat shock protein 32 (Hsp32)\/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib","volume":"111","author":"Sexl","year":"2008","journal-title":"Blood"},{"key":"46","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1046\/j.0007-1048.2002.03340.x","article-title":"A highly specific and sensitive fluorescence in situ hybridization assay for the detection of t(4;11)(q21;q23) and concurrent submicroscopic deletions in acute leukaemias","volume":"116","author":"Strehl","year":"2002","journal-title":"Br J Haematol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.12943","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T13:17:12Z","timestamp":1596719832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.12943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,27]]},"references-count":46,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2016,11,22]]}},"alternative-id":["12943","27801667"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.12943","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,27]]}}}